Where Can I Buy High-Quality Ara-290 Peptide Safely?
To buy high-quality Ara-290 safely, source it only from research suppliers that publish a batch-matched COA with 99%+ HPLC purity and ship cold. Ara-290 (cibinetide) is an erythropoietin-derived peptide studied for nerve repair and inflammation — with more human research behind it than many gray-market peptides, but still no marketing approval. This guide covers what Ara-290 is, how it works, what studies show, and how to verify a source.
Editorial & research disclaimer: This article is for educational purposes only and is not medical advice. Ara-290 (cibinetide) is an investigational compound; it is not an approved medicine in most jurisdictions and is sold for research use only. Always consult a licensed healthcare professional and verify local regulations before handling any peptide.
Quick Answer
Where can you buy high-quality Ara-290 safely? From US-based research-peptide suppliers that publish a recent, batch-matched COA showing 99%+ HPLC purity and independent third-party testing, lyophilize in cleanroom conditions, and ship cold. Ara-290 is investigational, not an approved drug, so supplier transparency and documentation are essential.
Ara-290 (also called cibinetide) is an 11-amino-acid peptide derived from the tissue-protective region of erythropoietin (EPO). Unlike EPO itself, it is designed to be tissue-protective and anti-inflammatory without stimulating red-blood-cell production.
Ara-290 (cibinetide) is an 11-amino-acid peptide derived from the tissue-protective helix of erythropoietin (EPO).
Mechanism: it activates the innate repair receptor (the EPOR/CD131 heteroreceptor) for anti-inflammatory, tissue-protective effects.
No erythropoiesis: unlike EPO, it is designed not to raise red blood cell counts.
Researched for neuropathic pain, small-fibre neuropathy (including in sarcoidosis), and inflammation — with some early human studies.
Still investigational: verify a batch-matched COA, 99%+ HPLC purity, and cold-chain shipping before buying.
Understanding Ara-290: What Is It?
Ara-290, also known as cibinetide, is an 11-amino-acid peptide derived from a specific region of erythropoietin (EPO) — the part responsible for EPO's tissue-protective effects rather than its blood-building effects. Researchers designed it to capture EPO's protective, anti-inflammatory signaling while avoiding the increase in red blood cells (and associated risks) that EPO itself causes.
- Derived from the tissue-protective region of erythropoietin.
- Focused on reducing inflammation and protecting tissue.
- Studied for nerve and tissue repair, especially small-fibre neuropathy.
- Does not stimulate red-blood-cell production like EPO.
How Does Ara-290 Work? The Innate Repair Receptor
EPO's protective effects are mediated not by the classic EPO receptor that drives red-cell production, but by a separate innate repair receptor (IRR) — a heteroreceptor combining the EPO receptor with the beta-common receptor (CD131). Ara-290 is engineered to selectively activate this innate repair receptor, triggering anti-inflammatory and tissue-protective signaling at sites of injury without the erythropoietic effect.
Ara-290 Uses: Therapeutic Applications in Research
Ara-290 has been investigated for several applications, and notably it has reached early human studies in some areas — more than can be said for many gray-market peptides, though it remains investigational.
- Neuropathic pain: reducing pain associated with small-fibre nerve damage.
- Small-fibre neuropathy: including in the context of sarcoidosis.
- Chronic inflammation: dampening inflammatory signaling via the innate repair receptor.
- Diabetes-related complications: explored for nerve and tissue protection.
What the Research Shows (and Its Limits)
Early-phase clinical research, including work in sarcoidosis-associated small-fibre neuropathy, has explored Ara-290 for pain and nerve-function endpoints, generally reporting a favorable tolerability profile in those small studies. That human research is a genuine point in its favor relative to purely preclinical compounds.
The honest limitation: Ara-290 remains investigational and is not an approved, marketed medicine in most jurisdictions. The existing human studies are early and limited in size, so efficacy and long-term safety are not firmly established. Treat strong therapeutic claims with caution.
How to Identify High-Quality Ara-290
As with any research peptide, documentation is your protection. Verify before purchasing:
| Factor | High-Quality (Verified) | Low-Quality / Offshore |
|---|---|---|
| Purity | 99%+ by HPLC, identity confirmed | Unverified, self-reported, or below 95% |
| COA | Batch-specific, recent, third-party lab | Missing, generic, undated, or photocopied |
| Manufacturing | Cleanroom, validated lyophilization | Sterility & environment unclear |
| Shipping | Cold-chain where required | Ambient; degradation risk |
| Labeling | Clear “research use only” | Mixed consumer/medical claims |
Where to Buy Ara-290 Safely
For an investigational peptide like Ara-290, research-peptide suppliers that meet the documentation standard above are the relevant channel — strictly for legitimate research use.
| Channel | Selection | Oversight | Best for |
|---|---|---|---|
| Research-peptide suppliers | Broad; specialized compounds | COA-driven; varies by vendor | Informed researchers who verify COAs |
| Licensed pharmacies / clinics | Limited / approved drugs only | High; professional oversight | Approved medications & guidance |
| General online marketplaces | Wide but unvetted | Low; highest variance | Generally not recommended |
Wherever you look, the checklist is fixed: COA + HPLC purity + lyophilization + cold-chain + batch traceability. Browse PrymaLab's research peptide catalog as a reference for these transparency standards.
Storage and Handling
- Store lyophilized vials cold and dark — refrigerate or freeze unopened material.
- Reconstitute with bacteriostatic water per the supplier's ratio, swirling gently.
- Refrigerate the reconstituted solution and use within the supplier's stated window.
- Use sterile technique and avoid freeze-thaw cycles. A reconstitution calculator helps you dose research solutions accurately.
Researching tissue-protective peptides? Source verified material.
PrymaLab focuses on US-handled research peptides with transparent, batch-specific COAs and cold-chain shipping.
Explore PrymaLab Research PeptidesFrequently Asked Questions
Where can I buy high-quality Ara-290 safely?
From US-based research-peptide suppliers that publish a recent, batch-matched COA showing 99%+ HPLC purity and independent third-party testing, lyophilize in cleanroom conditions, and ship cold. Ara-290 is investigational and not an approved drug, so supplier transparency and verifiable documentation are essential before purchasing.
What is Ara-290 (cibinetide)?
Ara-290, also called cibinetide, is an 11-amino-acid peptide derived from the tissue-protective region of erythropoietin (EPO). It is designed to capture EPO's protective, anti-inflammatory signaling without stimulating red-blood-cell production. It is studied for nerve repair and inflammation and remains an investigational compound.
How does Ara-290 work?
Ara-290 selectively activates the innate repair receptor — a heteroreceptor combining the EPO receptor with the beta-common receptor (CD131) — which mediates EPO's tissue-protective and anti-inflammatory effects. By targeting this receptor rather than the classic EPO receptor, it aims to protect tissue without raising red blood cell counts.
What is Ara-290 used for in research?
Ara-290 has been investigated for neuropathic pain, small-fibre neuropathy (including in sarcoidosis), chronic inflammation, and diabetes-related nerve and tissue complications. Some of this work has reached early human studies, though Ara-290 remains investigational and is not an approved, marketed medicine in most jurisdictions.
Does Ara-290 increase red blood cells like EPO?
No — that is the point of its design. Ara-290 is derived from EPO's tissue-protective region and selectively activates the innate repair receptor, so it aims to deliver protective, anti-inflammatory effects without the erythropoietic (red-blood-cell-stimulating) activity and associated risks of full EPO.
Is Ara-290 safe?
Early, small human studies have generally reported a favorable tolerability profile, which is more human data than many research peptides have. However, those studies are limited in size and Ara-290 remains investigational, so long-term safety is not firmly established. Consult a licensed professional and verify legality before any use.
Is Ara-290 legal to buy?
Ara-290 is sold for research use only and is not an approved medicine in most jurisdictions; legality varies by region, and buying it for personal use sits in a gray zone. Confirm your local regulations, and buy only from suppliers that label the product for research use only and require age verification.
What purity should Ara-290 have?
Look for 99% HPLC purity or higher with mass-spec identity confirmation on a batch-specific COA from an independent lab. Anything below 98% is a yellow flag and below 95% is a hard pass. Also confirm cold-chain shipping and proper storage, since peptides degrade with heat and light.
References & Further Reading
- Brines, M., et al. (2008). Nonerythropoietic, tissue-protective peptides derived from erythropoietin. PNAS, 105(31), 10925–10930.
- Dahan, A., et al. (2013). ARA-290 in sarcoidosis-related small-fibre neuropathy. Molecular Medicine, 19, 334–345.
- Brines, M., & Cerami, A. (2012). The receptor that tames the innate immune response. Molecular Medicine, 18, 486–496.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov. Accessed 2026.
PrymaLab resources: Research peptides · Research Hub · Peptide calculator · FAQ · About PrymaLab.
Final disclaimer: This article is for educational purposes only. Ara-290 and the other compounds discussed are sold for research purposes only and are not approved by the FDA or comparable agencies for human therapeutic use. Statements about their effects have not been evaluated by the FDA.
Always consult a licensed healthcare professional before starting any new health protocol, and verify the legal status of any compound in your jurisdiction. PrymaLab does not endorse any specific third-party peptide vendor mentioned in this article and assumes no responsibility for third-party products.